SCHEMBL1345256

SCHEMBL1345256

CCOC(=O)/C(=C/NC(C)(C)C)C(=O)c1cc(F)c(F)c(OC)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.37
NPSR1 Q6W5P4 5/20 0.36
MAPT P10636 7/20 0.35
LMNA P02545 5/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
DHODH Q02127 3/20 0.34
KDM4E B2RXH2 4/20 0.34
MAPK1 P28482 1/20 0.34
POLB P06746 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PLIN1 O60240 1/20 0.33
PLIN5 Q00G26 1/20 0.33
ABHD5 Q8WTS1 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HPGD P15428 2/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12130969 1.00 GAA (0.37) GAANPSR1MAPTLMNAMEN1
SCHEMBL1345257 1.00 GAA (0.37) GAANPSR1MAPTLMNAMEN1
SCHEMBL9686969 0.88 GAA (0.39) GAANPSR1MAPTLMNAMEN1
SCHEMBL9686966 0.88 GAA (0.39) GAANPSR1MAPTLMNAMEN1
SCHEMBL12916957 0.86 NPSR1 (0.37) GAANPSR1MAPTLMNAMEN1
SCHEMBL964755 0.84 NPSR1 (0.37) GAANPSR1MAPTLMNAMEN1
SCHEMBL964753 0.84 NPSR1 (0.37) GAANPSR1MAPTLMNAMEN1
SCHEMBL12916941 0.84 MAPT (0.35) GAANPSR1MAPTLMNAMEN1
SCHEMBL12427259 0.83 SMN1; SMN2 (0.37) GAANPSR1MAPTLMNAMEN1
SCHEMBL9221714 0.83 GAA (0.41) GAANPSR1MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013182-B1 AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2013-09-04 EP disclosed
EP-2383271-B1 Aminoquinolones as GSK-3 Inhibitors KYORIN SEIYAKU KK (JP) 2013-07-10 EP disclosed
US-8063221-B2 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
EP-2383271-A1 Aminoquinolones as GSK-3 Inhibitors Kyorin Pharmaceutical Co., Ltd. (JP) 2011-11-02 EP disclosed
EP-2013182-A2 AMINOQUINOLONES AS GSK-3 INHIBITORS Activx Biosciences, Inc. (US) 2009-01-14 EP disclosed
US-20070254866-A1 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
WO-2007106537-A2 AMINOQUINOLONES AS GSK-3 INHIBITORS ACTIVX BIOSCIENCES, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254866-A1 Aminoquinolones as GSK-3 inhibitors GSK3B, GSK3A, GSKIP GAA 2384/4885NPSR1 4749/4885MAPT 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.